Literature DB >> 21046289

Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.

Megan M Donohue1, David L Tirschwell.   

Abstract

Our knowledge of the pharmacogenetics of warfarin and clopidogrel continues to expand as we learn more about the individual genetic variations that contribute to the drugs' efficacy and toxicity. We aim to review the recent developments in the field and discuss the clinical implications for the treatment of ischemic stroke patients. Despite recent advances, there is still insufficient data to suggest that routine genetic testing improves outcomes in patients treated with warfarin or clopidogrel for prevention of stroke.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21046289     DOI： 10.1007/s11910-010-0157-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  50 in total

1.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

2.  Pharmacogenetics of coumarinic oral anticoagulants.

Authors:  Vangelis G Manolopoulos; Georgia Ragia; Anna Tavridou
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

3.  Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

Authors:  Chun Li; Ute I Schwarz; Marylyn D Ritchie; Dan M Roden; C Michael Stein; Daniel Kurnik
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

4.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

5.  A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Authors:  D Voora; D C Koboldt; C R King; P A Lenzini; C S Eby; R Porche-Sorbet; E Deych; M Crankshaw; P E Milligan; H L McLeod; S R Patel; L H Cavallari; P M Ridker; G R Grice; R D Miller; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-03-03       Impact factor: 6.875

6.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.

Authors:  Michael A Hillman; Russell A Wilke; Steven H Yale; Humberto J Vidaillet; Michael D Caldwell; Ingrid Glurich; Richard L Berg; John Schmelzer; James K Burmester
Journal:  Clin Med Res       Date:  2005-08

7.  Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Authors:  Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati
Journal:  Circulation       Date:  2010-01-18       Impact factor: 29.690

8.  The largest prospective warfarin-treated cohort supports genetic forecasting.

Authors:  Mia Wadelius; Leslie Y Chen; Jonatan D Lindh; Niclas Eriksson; Mohammed J R Ghori; Suzannah Bumpstead; Lennart Holm; Ralph McGinnis; Anders Rane; Panos Deloukas
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

9.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

Authors:  Deanna L Kroetz; Christiane Pauli-Magnus; Laura M Hodges; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Doug Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Elaine J Carlson; Ira Herskowitz; Kathleen M Giacomini; Andrew G Clark
Journal:  Pharmacogenetics       Date:  2003-08

10.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321
View more
  5 in total

Review 1.  Pharmacogenomics of anti-platelet and anti-coagulation therapy.

Authors:  Adam S Fisch; Christina G Perry; Sarah H Stephens; Richard B Horenstein; Alan R Shuldiner
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

2.  Gene-drug interaction in stroke.

Authors:  Serena Amici; Maurizio Paciaroni; Giancarlo Agnelli; Valeria Caso
Journal:  Stroke Res Treat       Date:  2011-11-10

Review 3.  Genome-Wide Studies in Ischaemic Stroke: Are Genetics Only Useful for Finding Genes?

Authors:  Cristina Gallego-Fabrega; Elena Muiño; Jara Cárcel-Márquez; Laia Llucià-Carol; Miquel Lledós; Jesús M Martín-Campos; Natalia Cullell; Israel Fernández-Cadenas
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

4.  Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Changcheng Shi; Wei Yan; Gang Wang; Fei Wang; Qingyu Li; Nengming Lin
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

Review 5.  Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

Authors:  Natalia Cullell; Caty Carrera; Elena Muiño; Nuria Torres; Jerzy Krupinski; Israel Fernandez-Cadenas
Journal:  Oncotarget       Date:  2018-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.